EEC Startup Review

Viriome Sp. z o.o. is developing an innovative bacteriophage-based platform for mRNA delivery that has the potential to revolutionize cancer treatment. Our technology enables precise gene therapy delivery, reducing costs and increasing accessibility to treatment. The concept has been validated by experts, and we are now preparing for the PoC. The market for this technology is valued at $8.03 billion, with our solution having the potential to capture a 5-15% share. Viriome is led by two key founders: Filip – a biotechnology enthusiast and the main creator of the solution, and Kacper – an experienced manager with years of expertise in team and project management. They are supported by a scientific advisory board comprising professors and doctors. The startup secured 4th place at CEE DeepTech Days 2024 and is participating in the Unicorn Hub 2.0 program. We collaborate with top-tier subcontractors and intermediaries. We are seeking investors, strategic partners, and innovation brokers.

Galeria zdjęć